c-Abl (ABL1) phosphorylates α-synuclein at Y39, promoting aggregation and neuronal toxicity. Nilotinib (FDA-approved for CML) inhibits c-Abl and promotes α-syn clearance via autophagy, representing a rapid translational candidate. However, the hypothesis faces significant challenges: (1) Y39 phosphorylation is less abundant than S129 in human synucleinopathies and its aggregation role is contested; (2) Nilotinib failed its primary endpoint in PD clinical trials (Ko et al. 2020) with no UPDRS improvement; (3) BBB penetration claims are disputed; (4) Nilotinib has multiple off-target effects (DDR1, DDR2) that may explain any apparent neuroprotection independent of c-Abl. The Mechanism Attribution Problem is severe—any observed benefit cannot be confidently assigned to c-Abl inhibition.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["ABL1/c-Abl Tyrosine Kinase Activation"]
B["Mitochondrial Dysfunction"]
C["Oxidative Stress"]
D["p53 Activation Pro-apoptotic Signaling"]
E["Synaptic Dysfunction"]
F["Neuronal Death"]
G["Dasatinib / Nilotinib Kinase Inhibition"]
A --> B
B --> C
C --> D
D --> F
A --> E
E --> F
G --> A
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
8 citations1 with PMIDValidation: 0%4 supporting / 4 opposing
✓For(4)
No supporting evidence
No opposing evidence
(4)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
4
MECH 4CLIN 4GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
c-Abl phosphorylates α-syn at Y39 promoting aggreg…
Nilotinib crosses BBB and reduces α-syn in preclinical models
c-Abl activity elevated in PD substantia nigra; PMID related
Nilotinib FDA-approved for CML—established safety and manufacturing
✗ Opposing Evidence
4
Ko et al. 2020 trial failed primary endpoint (UPDRS)—no clinical efficacy despite CSF α-syn reduction
Y39 phosphorylation is minor modification vs S129; role in aggregation contested
Nilotinib has multiple off-target kinases (DDR1, DDR2); benefit cannot be attributed to c-Abl
BBB penetration claims disputed—therapeutic concentrations in SN uncertain
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-26 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Legacy Pre-Pipeline Hypotheses: Neurodegeneration
Hypothesis 1: Exosomal α-Synuclein as an Interneuronal Propagation Vector in Parkinson's Disease
Mechanism: Misfolded α-synuclein (aSyn) aggregates are transmitted via exosomes from donor to recipient neurons, templating endogenous aSyn misfolding through a "prion-like" mechanism. This explains the stereotypical progression of Lewy pathology in Braak staging.
This assessment evaluates each hypothesis across five critical domains using a standardized framework. Evidence strength, translational readiness, and development feasibility are rated on consistent scales to enable cross-hypothesis comparison. Where the Skeptic's revised confidence scores diverge from my independent assessment, I note the discrepancy and rationale.
IF ABL1 knockout or ABL1 Y245F kinase-dead knock-in neurons are challenged with preformed α-synuclein fibrils, THEN Y39-phosphorylated α-synuclein will be reduced by >70% and aggregate burden will decrease compared to wild-type neurons, confirming ABL1 drives Y39 phosphorylation independent of off-target effects.
pendingconf: 0.55
Expected outcome: Y39-pS129 double-positive inclusions will be reduced by >70% in ABL1-deficient neurons; autophagy flux markers (LC3-II/LC3-I ratio) will not differ from baseline, indicating the clearance effect is c-Abl-dependent.
Falsified by: If Y39 phosphorylation and aggregate burden do not differ between ABL1 knockout and wild-type neurons (difference <20%), Y39 phosphorylation is driven by kinases other than ABL1 and the hypothesis is falsified; alternatively, if aggregate reduction occurs via autophagy induction despite absent c-Abl, nilotinib's mechanism is autophagy-induction rather than c-Abl inhibition.
Method: Human iPSC-derived dopaminergic neurons from 3 PD patients and 3 age-matched controls; CRISPR/Cas9-mediated ABL1 knockout via exon 2 deletion; α-synuclein PFF seeding assay at DIV 21; sequential extraction (TBS-soluble, Triton-soluble, SDS-insoluble) with immunoblot for Y39 (Abcam ab168381) and total α-synuclein (Syn1 BD Biosciences); 21-day treatment duration.
IF patients with idiopathic PD receive 6 months of nilotinib (300mg daily, the dose used in the Ko et al. 2020 trial) plus standard dopaminergic therapy versus placebo plus standard therapy, THEN striatal dopamine turnover (measured by F-DOPA PET) will show no significant difference between groups, indicating nilotinib provides no disease-modifying effect beyond symptomatic treatment.
pendingconf: 0.35
Expected outcome: No significant difference in F-DOPA Ki values between nilotinib and placebo groups after 6 months; projected effect size <0.15 standardized units.
Falsified by: If nilotinib-treated patients show ≥15% improvement in F-DOPA Ki at 6 months compared to placebo (p<0.05), the hypothesis that nilotinib's neuroprotective effects are attributable to c-Abl inhibition (and not off-target mechanisms) would be supported; however, this would require mechanistic replication with selective ABL1 inhibitors.
Method: Re-analysis of Ko et al. 2020 (NCT02954978) F-DOPA PET data, stratified by nilotinib pharmacokinetic exposure (plasma levels) and DDR1/DDR2 genotyping to test whether higher c-Abl target engagement (rather than total drug exposure) predicts outcomes.
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
3D Protein Structure
🧬
ABL1 — Search for structure
Click to search RCSB PDB